Circulating apoptotic progenitor cells in patients with congestive heart failure.
BACKGROUND
Circulating CD34+ endothelial progenitor cells (EPCs) are capable of differentiating into mature endothelial cells to assist in angiogenesis and vasculogenesis. We sought to quantify the numbers of apoptotic progenitors in patients with congestive heart failure.


RESULTS
Peripheral blood mononuclear cells were isolated by Ficoll density-gradient from 58 patients with various degrees of heart failure and 23 matched controls. Apoptosis in progenitor CD34+ cells was assessed using the Annexin V-PE/PI detection kit, and FACS analysis was performed with triple staining for CD34, annexin-V and propidium iodide. The percentage of early and late apoptotic progenitor cells was determined in the subject groups and was correlated with clinical characteristics. While there was no significant difference in total CD34 positive cells or early apoptotic progenitors between control subjects and CHF patients (p = 0.42) or between severe and mild/moderate CHF groups (p = 0.544), there was an elevated number of late apoptotic progenitors in the severe CHF group compared with the mild/moderate CHF group (p = 0.03). Late apoptotic progenitors were significantly increased in CHF patients as compared to matched controls. There was also an inverse correlation between late apoptotic progenitors and ejection fraction (r = -0.252, p = 0.028) as well as a positive association with NYHA class (r = 0.223, p = 0.046).


CONCLUSIONS
Severe heart failure patients exhibited higher numbers of late apoptotic progenitors, and this was positively associated with NYHA class and negatively correlated with ejection fraction. This finding may shed light on the numerous factors governing the pathophysiology of CHF.
Geft
Dael
D
Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Schwartzenberg
Shmuel
S
Rogowsky
Ori
O
Finkelstein
Ariel
A
Ablin
Jacob
J
Maysel-Auslender
Sofia
S
Wexler
Dov
D
Keren
Gad
G
George
Jacob
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018952:Antigens, CD34 / Q000096:biosynthesis; D017209:Apoptosis; D002454:Cell Differentiation; D005260:Female; D006333:Heart Failure / Q000097:blood* / Q000473:pathology*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000166:cytology; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D009389:Neovascularization, Pathologic; D013234:Stem Cells / Q000166:cytology*
D018952:Antigens, CD34
Circulation. 2000 Jul 18;102(3):351-6
10899101
Arterioscler Thromb Vasc Biol. 2007 May;27(5):e27-31
17332488
Hypertension. 2001 Dec 1;38(6):1451-5
11751734
N Engl J Med. 2003 May 15;348(20):2007-18
12748317
Nat Med. 2003 Jun;9(6):702-12
12778169
Am Heart J. 2003 Jun;145(6):962-70
12796750
Heart. 2003 Aug;89(8):871-4
12860861
Blood Coagul Fibrinolysis. 2003 Sep;14(6):515-21
12960603
Front Biosci. 2004 May 1;9:1118-35
14977533
Eur J Clin Invest. 2004 Jun;34(6):392-401
15200490
Clin Exp Pharmacol Physiol. 2004 Jul;31(7):407-13
15236625
Circ Res. 2004 Aug 20;95(4):343-53
15321944
Blood. 1991 Jan 15;77(2):400-9
1702334
Biochim Biophys Acta. 1994 Apr 5;1197(1):63-93
8155692
Blood. 1994 Sep 1;84(5):1415-20
8068938
J Exp Med. 1995 Nov 1;182(5):1545-56
7595224
Heart. 2007 Sep;93(9):1046-50
17277352
N Engl J Med. 2008 May 15;358(20):2148-59
18480207
Science. 1997 Feb 14;275(5302):964-7
9020076
Circ Res. 1999 Aug 6;85(3):221-8
10436164
Transfusion. 1999 Aug;39(8):864-72
10504123
Circulation. 2004 Nov 16;110(20):3213-20
15533859
Blood. 2004 Dec 1;104(12):3591-7
15161665
J Cell Mol Med. 2004 Oct-Dec;8(4):498-508
15601578
Blood. 2005 Jan 1;105(1):199-206
15345590
Eur Heart J. 2005 Jan;26(1):65-9
15615801
Eur Heart J. 2005 Jun;26(12):1196-204
15734770
Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):112-6
16239600
Eur J Heart Fail. 2006 Jan;8(1):58-62
16061420
Arterioscler Thromb Vasc Biol. 2006 Feb;26(2):257-66
16322535
J Am Coll Cardiol. 2006 Oct 17;48(8):1538-47
17045885
Circulation. 2001 Nov 27;104(22):2649-52
11723013